Literature DB >> 21814780

Treatment of epidermal growth factor receptor inhibitor-induced skin toxicities: do the data support the current practice?

Jonathan Cotliar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21814780     DOI： 10.1007/s00520-011-1234-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  5 in total

1.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Authors:  Mario E Lacouture; Edith P Mitchell; Bilal Piperdi; Madhavan V Pillai; Heather Shearer; Nicholas Iannotti; Feng Xu; Mohamed Yassine
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

2.  Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

Authors:  Aminah Jatoi; Shaker R Dakhil; Jeff A Sloan; John W Kugler; Kendrith M Rowland; Paul L Schaefer; Paul J Novotny; Donald B Wender; Howard M Gross; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-09-06       Impact factor: 3.603

3.  Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.

Authors:  Susan L Boone; Alfred Rademaker; Dachao Liu; Carmen Pfeiffer; David J Mauro; Mario E Lacouture
Journal:  Oncology       Date:  2007-12-21       Impact factor: 2.935

4.  Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).

Authors:  Aminah Jatoi; Kendrith Rowland; Jeff A Sloan; Howard M Gross; Paul A Fishkin; Stephen P Kahanic; Paul J Novotny; Paul L Schaefer; David B Johnson; Loren K Tschetter; Charles L Loprinzi
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

5.  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.

Authors:  Alon Scope; Anna Liza C Agero; Stephen W Dusza; Patricia L Myskowski; Jocelyn A Lieb; Leonard Saltz; Nancy E Kemeny; Allan C Halpern
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.